Literature DB >> 573934

Clinical effect and metabolism of S-sulfonated immunoglobulin in 7 patients with congenital humoral immunodeficiency.

T Yamanaka, W Abo, S Chiba, T Nakao, Y Masuho, K Tomibe, T Noguchi.   

Abstract

7 patients with primary humoral immunodeficiency were given an S-sulfonated IgG preparation, 100 mg/kg i.v. at intervals of 3--4 weeks, for treatment of, or prophylaxis against, infection. The clinical effects and metabolism of S-sulfonated IgG were studied. No side reactions attributable to S-sulfonated IgG occurred in any of the patients. The S-sulfonated IgG was completely transformed into intact IgG within 24 h after administration, and had a mean half-life of 21 days, comparable to that of intact IgG. Complete restoration of IgG Fc fragment activity occurred within 24 h following injection, as assessed by reversed passive cutaneous anaphylaxis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 573934     DOI: 10.1111/j.1423-0410.1979.tb02263.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  Clinical trial of sulfonated immunoglobulin preparation for intravenous administration. I. Replacement therapy for primary immunodeficiency syndromes.

Authors:  N Kobayashi; N Gohya; S Matsumoto
Journal:  Eur J Pediatr       Date:  1981-05       Impact factor: 3.183

2.  Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP).

Authors:  Y Machino; H Ohta; E Suzuki; S Higurashi; T Tezuka; H Nagashima; J Kohroki; Y Masuho
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.